Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Interferon Treatment Eradicates a New Human Coronavirus in a Culture Model

By BiotechDaily International staff writers
Posted on 06 Mar 2013
A recently recognized human coronavirus was treated successfully in an in vitro model based on human bronchial epithelial tissue, which reduces fears that the virus might be capable of setting off a worldwide respiratory disease pandemic.

The recent emergence of a novel human coronavirus (HCoV-EMC) in the Middle East raised considerable concerns, as it was found to be associated with severe acute pneumonia, renal failure, and fatal outcome and thus resembled the clinical presentation of severe acute respiratory syndrome (SARS) observed in 2002 and 2003. Like SARS-CoV, HCoV-EMC is of zoonotic origin and closely related to bat coronaviruses.

To get a handle on this potentially fatal pathogen, investigators at Kantonal Hospital (St. Gallen, Switzerland) developed an in vitro model based on human bronchial epithelial cells, which are highly susceptible to HCoV-EMC infection and in which the virus is able to multiply at a faster initial rate than the SARS virus. The investigators employed advanced genomic research tools such as reverse transcription (RT)-PCR and RNAseq data to experimentally determine the identity of seven HCoV-EMC subgenomic mRNAs.

Results published in the February 19, 2013, online edition of the journal mBio revealed that while the human bronchial epithelial cells were readily responsive to type I and type III interferon (IFN), neither a pronounced inflammatory cytokine nor any detectable IFN responses were found following HCoV-EMC infection, suggesting that innate immune evasion mechanisms and possible IFN antagonists of the virus were operational in the human host. On the other hand, type I and type III IFN were found to efficiently reduce HCoV-EMC replication in the human cell cultures, providing a possible treatment option in cases of suspected HCoV-EMC infection.

"Surprisingly, this coronavirus grows very efficiently on human epithelial cells," said senior author Dr. Volker Thiel, a senior research fellow at Kantonal Hospital. "The other thing we found is that the viruses (HCoV-EMC, SARS, and the common cold virus) are all similar in terms of host responses: they do not provoke a huge innate immune response. We do not know whether the cases we observe are the tip of the iceberg, or whether many more people are infected without showing severe symptoms."

Related Links:
Kantonal Hospital



RANDOX LABORATORIES
SLAS - Society for Laboratory Automation and Screening
BIOSIGMA S.R.L.
comments powered by Disqus

Channels

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: On target: When researchers introduced nanobodies they made to cells engineered to express a tagged version of a protein in skeletal fibers known as tubulin (red), the nanobodies latched on. The cells above have recently divided (Photo courtesy of Rockefeller University).

Turning Antibodies into Precisely Tuned Nanobodies

New technology has the potential to create nanobodies making them much more accessible than antibodies for all sorts of research. Antibodies control the process of recognizing and zooming in on molecular... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.